Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
about
Interferon alpha for the adjuvant treatment of cutaneous melanomaMalignant melanoma mimicking giant cell variant of glioblastoma multiforme: a case report and review of literatureModel-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework.Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]Melanoma in pediatric, adolescent, and young adult patients.Treatment of malignant melanoma.Interferon-alpha therapy for melanoma.Adjuvant therapy in melanoma.A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.An update on adjuvant interferon for melanoma.Assessing outcomes in palliative chemotherapy.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Intratumoral immunotherapy: using the tumour against itself.Adjuvant therapy for melanoma: How should we respond to high-dose interferon?Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patientsAugmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.Cancer immunotherapies, their safety and toxicity.Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.Latest approved therapies for metastatic melanoma: what comes next?Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.Quality adjusted survival analysis with repeated quality of life measures.Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study.Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
P2860
Q24201908-0B116EE0-F013-4E37-A7AD-68DB7644BDFBQ26801928-A7CA52F1-0EF8-4773-B1AD-022C23A680C1Q30768835-3A3F767D-36DD-493E-96E9-0A9D7F73768FQ33234917-092DBACF-FB26-4FE1-898A-223F4014161DQ33554622-8700E425-D2A8-4335-B1C4-805685CB1569Q33689227-0653BA8F-0645-4AF5-BABD-8EC68E013686Q33836075-C42AA250-623D-4FB7-ADB7-C3E7E7579213Q34067633-DE72AE1E-525C-4917-BA60-FAB328574FF7Q34241208-8BA0A72E-E797-4675-9DC4-2B1154D8912AQ34573032-58F82A80-9B3F-4B58-ACE5-B12C0D3A3F85Q34660752-C9CF641B-0252-418A-A448-4E23B69E752BQ35034768-D96DAD69-9065-4B1E-8F25-4EEA938BCE02Q35988030-B9AF6C21-5342-42DB-BD19-33BCEACA1DE6Q36292432-544A8F51-4B3C-4062-BAC1-6B6E1DEA3D6FQ36613860-3E063D00-6E39-4AA6-88B5-846ABF87E808Q36641817-EC22F8D4-E6AC-4D11-B88D-39E02B20D3BAQ36779843-2E686FE5-F1DB-484E-B114-C6A92552749DQ36906147-ED4AC049-ABE2-45C3-A883-DEDB651A2569Q37003295-771B4BF4-DEF8-4967-B8D1-4BBA9F0EDCECQ38018370-35EC686B-5035-4501-A4A3-E54608FABB53Q38106230-00569A1F-2958-4636-853A-098C929917D2Q40873936-29141E3E-582E-4116-B5E2-C397F608A7B1Q41206469-16AB2BB6-6C48-422A-B4FC-18A8B6119D85Q43202126-8B7ED3A0-C5DC-4BE6-BF85-8B593CCDE019Q44026353-B07CEEF3-3C56-4E8F-B1A6-F80ED5274DDEQ45901589-09F54366-1DD9-45D9-9509-291C2D74F32BQ48293819-04AB8913-3CE9-4FAD-8EB0-B35AAE849324Q53558519-3C48E0C7-F7D0-436F-A487-556F7941A4EC
P2860
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@en
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@nl
type
label
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@en
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@nl
prefLabel
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@en
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@nl
P2093
P1476
Quality-of-life-adjusted survi ...... perative Oncology Group study.
@en
P2093
A Goldhirsch
J M Kirkwood
R D Gelber
P304
P356
10.1200/JCO.1996.14.10.2666
P407
P577
1996-10-01T00:00:00Z